Effectiveness of add-on Pegylated interferon alfa-2a therapy in a Lamivudine-treated patient with chronic hepatitis B
Journal Title: Annals of Hepatology - Year 2011, Vol 10, Issue 1
Abstract
Hepatitis B virus (HBV) surface antigen (HBsAg) to anti-HBsAg (anti-HBs) antibody seroconversion is the best, final objective for all available chronic hepatitis B (CHB) treatments. Unfortunately, this goal is rarely obtained with the currently utilized therapeutic approaches. Here we describe the case of a CHB patient who was very successfully treated with a particular therapeutic schedule. The patient was initially treated with Lamivudine for four years. Subsequently, pegylated interferon alpha-2a was introduced for a period of one year. During this period of combined therapies, the patient showed a flare of aminotransferase values followed by complete normalization of liver biochemistry parameters and HBsAg/anti-HBs seroconversion that persisted up to 24 months after all therapies had been stopped.
Authors and Affiliations
Carmelo Mangano, Giovanni Squadrito, Irene Cacciola, Mariastella Carpentieri, Giuseppe Foti
Venlafaxine-Induced Hepatotoxicity in a Patient with Ulcerative Colitis
Dendritic cells in NASH: Friend or foe?
Antioxidant effect of N-acetylcysteine on prehepatic portal hypertensive gastropathy in rats
Background. Portal hypertension is a clinical syndrome associated with the development of a hyperdynamic circulation and gastroesophageal varices. Aim. To evaluate the antioxidant effect of N-acetylcysteine on portal hyp...
Hepatitis E virus serum antibodies and RNA prevalence in patients evaluated for heart and kidney transplantation
Background. Acute hepatitis E virus (HEV) infection in solid organ transplant recipients is rare, but cancause severe hepatic and extrahepatic complications. We sought to identify the pretransplant prevalenceof HEV infec...
The Annals of Hepatology welcomes the Canadian Association for the Study of the Liver (CASL)